HalioDx
Providing oncologists and biopharma with first-in-class immune-based diagnostic products and services.
- dt and ls
- biotechnology
- horizon europe
- biotech and pharma
- woman founder
- spinout
- radar de l'innovation
- risk management
- analytics
- testing
- tech for business
- oncology
- eit ecosystem
- observatoire industrial tech
- predictive analytics
- observatoire deeptech
- medical testing
- eit health
- biotech, medtech and e-health
- eit supernovas
- go global (eit health)
- go global 2019 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
€260m Valuation: €260m | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2015 | 2016 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 23417 % |
| EBITDA | 0000 | 0000 |
| % EBITDA margin | (410 %) | (18 %) |
| Profit | 0000 | 0000 |
| % profit margin | (433 %) | (3 %) |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
HalioDx was founded with a vision to revolutionize the field of precision medicine. The company was established by a team of innovative scientists and entrepreneurs, although specific names of the founders are not readily available. HalioDx focused on developing diagnostic solutions that enable personalized treatment for cancer patients, leveraging the power of immuno-oncology.
The company quickly gained recognition for its unique approach to diagnostics, which combined advanced biomarker technologies with a deep understanding of the tumor microenvironment. This allowed HalioDx to provide critical insights into how a patient's immune system interacts with cancer, thus guiding more effective treatment strategies.
A significant milestone in HalioDx's journey was its acquisition by Veracyte in 2021. This acquisition was a strategic move that expanded Veracyte's capabilities in the field of cancer diagnostics, integrating HalioDx's innovative solutions into its portfolio. The merger aimed to accelerate the development and commercialization of advanced diagnostic tests, ultimately improving patient outcomes in oncology.
Through its journey, HalioDx has remained committed to advancing precision medicine, continually pushing the boundaries of what is possible in cancer diagnostics. The company's story is a testament to the impact of innovative science and strategic partnerships in transforming healthcare.